This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Takeda 'Oral Velcade' Posts Strong Results in Multiple Myeloma Study

The most significant safety drawback of Velcade is peripheral neuropathy, or nerve damage to that causes numbness and pain.

In the phase II study of MLN9708, 32% of patients reported peripheral neuropathy, although most cases were minor. Two patients in the study, or 3%, reported more serious "grade 3" peripheral neuropathy.

Kumar called the relatively low incidence of serious peripheral neuropathy in the MLN9708 study "encouraging" and suggests that the drug's better tolerability profile could lead to longer treatment duration and better response rates.

The most common adverse events associated with MLN9708 were vomiting, diarrhea and rash occurring in about 40% of patients.

Takeda is conducting two phase III studies of MLN9708 in relapsed refractory multiple myeloma and amyloidosis, respectively. A third phase III study of MLN9708 in newly diagnosed multiple myeloma will begin next year.

Onyx Pharmaceuticals (ONXX) is developing its own oral proteasome inhibitor, known as oprozomib, and early stage data is being presented at this week's ASH meeting as well. Onyx's first proteasome inhibitor Kyprolis, which like Velcade is given via injection, was recently approved for the treatment of multiple myeloma and early sales have been strong.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ONXX $0.00 0.00%
CELG $112.35 -0.28%
AAPL $118.03 -0.71%
FB $105.41 -0.31%
GOOG $748.15 -0.02%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs